Roivant Sciences Ltd

NASDAQ:ROIV 4:00:00 PM EDT

10.90

-0.04 (-0.37%)

5:41:06 PM EDT: $11.00 +0.10 (+0.92%)

Market Cap (Intraday)	8.78B
Current PE	2.07
Forward PE	2.07
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$32.42 Million
Adjusted EPS	-$0.28

See more estimates

10-Day MA	$10.78
50-Day MA	$10.94
200-Day MA	$10.64

See more pivots

Roivant Sciences Ltd Stock, NASDAQ:ROIV

50 Broadway, 7th Floor, London, Greater London SW1H 0BD

Bermuda

Phone: +44.207.400.3347

Number of Employees: 904

http://www.roivant.com

Description

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.